• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[强化抗精神病药物治疗对精神分裂症的影响及停用抗精神病药物后的病程]

[Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].

作者信息

Steiner S

出版信息

Psychiatr Clin (Basel). 1980;13(3-4):165-78.

PMID:7244281
Abstract

Since 1976 a group of 229 patients with schizophrenic or other paranoid illness (9 patients) were treated for about 14 weeks with intramuscular or intravenous injections of fluphenazinedecanoate. During the first 2 weeks, three injections of 250 mg were given after which time the injections were given at three weekly intervals with slowly decreasing dosage. The patients also received tablets of procyclidine and 100-150 mg of amitriptyline per os. After the initial intensive phase the patients received an average of 145 mg i.m. every 3 weeks. A total of 209 patients could be followed up. Of those, 127 had for various reasons not continued with oral medication. The course of their illnesses was compared with that of the patients who had complied. The present report which represents a 3-year follow-up study confirms the findings of an earlier paper which showed the rapid onset and stability of remission, the absence of relapses among the patients who were under continued treatment, and the relative freedom from relapses among the patients who did not continue to have further neuroleptic medication. The anticipation that the initial high-dosage medication would have deleterious effects on the personality, producing robots or zombies, was shown to be groundless.

摘要

自1976年以来,一组229例精神分裂症或其他偏执性疾病患者(其中9例)接受了为期约14周的氟奋乃静癸酸酯肌肉注射或静脉注射治疗。在最初的2周内,给予3次250mg的注射,之后每隔3周注射一次,剂量逐渐减少。患者还口服了普环啶片和100 - 150mg的阿米替林。在最初的强化治疗阶段之后,患者平均每3周接受145mg的肌肉注射。共有209例患者能够得到随访。其中,127例因各种原因未继续口服药物治疗。将他们的病程与依从治疗的患者进行了比较。本报告是一项为期3年的随访研究,证实了早期一篇论文的研究结果,该研究表明缓解起效迅速且稳定,持续接受治疗的患者无复发,未继续使用抗精神病药物的患者相对较少复发。最初认为高剂量药物治疗会对人格产生有害影响,导致患者变成“机器人”或“行尸走肉”的预期被证明是毫无根据的。

相似文献

1
[Modification of schizophrenia by intensive neuroleptic therapy and the course of the disease after withdrawal of neuroleptic drugs].[强化抗精神病药物治疗对精神分裂症的影响及停用抗精神病药物后的病程]
Psychiatr Clin (Basel). 1980;13(3-4):165-78.
2
Depressive symptoms in chronic schizophrenic patients after withdrawal of long-acting neuroleptics.长效抗精神病药物撤药后慢性精神分裂症患者的抑郁症状
J Clin Psychiatry. 1983 Oct;44(10):369-71.
3
Relapse in chronic schizophrenics treated with fluphenazine decanoate is associated with low serum neuroleptic levels.用癸酸氟奋乃静治疗的慢性精神分裂症患者复发与血清抗精神病药物水平低有关。
J Clin Psychiatry. 1986 May;47(5):247-8.
4
[Antiparkinson drugs in neuroleptic treatment: comparative study of progressive and abrupt withdrawal].
Encephale. 1995 May-Jun;21(3):209-15.
5
Serum neuroleptic levels and clinical outcome in schizophrenic patients treated with fluphenazine decanoate.接受癸酸氟奋乃静治疗的精神分裂症患者的血清抗精神病药物水平与临床疗效
J Clin Psychopharmacol. 1985 Jun;5(3):143-7.
6
Impact of clinical pharmacokinetics on neuroleptic therapy in patients with schizophrenia.临床药代动力学对精神分裂症患者抗精神病药物治疗的影响。
J Psychiatry Neurosci. 1994 Jul;19(4):254-64.
7
Double-blind placebo substitution: withdrawal of fluphenazine decanoate in schizophrenic patients.双盲安慰剂替代:精神分裂症患者中癸酸氟奋乃静的撤药研究
J Clin Psychiatry. 1982 May;43(5):195-6.
8
Neuroleptic withdrawal with remitted schizophrenics: a naturalistic follow-up study.
Psychiatry. 2007 Spring;70(1):68-79. doi: 10.1521/psyc.2007.70.1.68.
9
Persistence of fluphenazine in plasma after decanoate withdrawal.癸酸酯停药后氟奋乃静在血浆中的持续存在。
J Clin Psychopharmacol. 1988 Feb;8(1):53-6.
10
Neuroleptic-induced supersensitivity psychosis: retrospective study of schizophrenic inpatients.抗精神病药物所致超敏性精神病:对精神分裂症住院患者的回顾性研究。
J Clin Psychiatry. 1988 Jul;49(7):258-61.